3sbio, Inc. · HKEX:1530
3sbio — FY2022 Earnings Presentation
46 slides from 3sbio's earnings presentation, Mar 21, 2023
Slide 1: 2022 Annual Results Presentation
2022 Annual Results Presentation 21 March, 2023
Slide 2: Disclaimer
Disclaimer This document has been prepared by 3SBio Inc. (the "Company") solely for selected recipients for information purposes only. You must read the terms, conditions, limitations, notifications, restrictions, acknowledgments and representations in the following (collectively, the "Terms") befor
Slide 3: Agenda
Agenda 01 02 03 04 05 Business R&D Financial 2022 Highlights Q&A Overview Review 3
Slide 4: 2022 Highlights
01 2022 Highlights Chairman, Director & CEO Dr. Jing LOU
Slide 5: 2022 Financial Highlights
2022 Financial Highlights Revenue NI Attributable to Parent Norm NI Attributable to Parent RMB Bn RMB Bn 2.2 RMB Bn 6.9 1.7 6.4 1.9 1.4 25.2% 5.6 1.7 1.2 1.2 5.3 4.6 1.3 1.0 16.7% 0.8 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 RMB 0.78 EPS 0.65 YoY +7.5% YoY +16.0% 0.
Slide 6: 2022 Highlights
2022 Highlights Biopharmaceuticals Hair Healthiness CDMO R&D TPIAO® EPIAO® SEPO® Mandi Mandi white YSP Pre-filled Remitch bottle Injection 4 Yisaipu® Cipterbin® Mandi Pro Mandi Mandi Foam Chemicals Shampoo submitted ANDA Core product revenue Core product revenue External order revenue 8 NDA/ANDA sub
Slide 7: 2022 Key Milestones
2022 Key Milestones R&D Hair Healthiness Advanced Key Candidates to the Late Clinical Stage Biopharmaceuticals Jun. 2022 Phase Ib clinical trial of TPIAO in CLDT completed all Top Brand in Hair CDMO subjects enrollment Healthiness Aug-Dec. 2022 Phase Ib study of Core Biopharmaceuticals anti-IL-1β mA
Slide 8: MSCI ESG Rating: Upgraded to AA
MSCI ESG Rating: Upgraded to AA Social Contribution LAST UPDATE: November 28, 2022 MISSION Making innovative biopharmaceuticals within the reach Environment VISION Social Based in China, the Group aspires to be a leading global biopharmaceutical Responsibility company VALUES Universe: MSCI ACWI Inde
Slide 9: Business Overview
02 Business Overview
Slide 10: Biopharmaceuticals
1 0 Biopharmaceuticals
Slide 11: TPIAO - Exclusive Commercialized rhTPO Product
TPIAO- Exclusive Commercialized rhTPO Product Revenue of TPIAO, 2022 Top 1 Market Share 1 65% 1 market share in term of sales, the largest market share in platelet therapy area RMB Mn YOY：10.3% 64.8% TPIAO 3,397 3,080 2,763 Product A (Class Interleukin) 2,323 1,670 Product B (Class TPO-RA) 2018 2019
Slide 12: TPIAO - Clear Mechanism Brought Great Advantages
TPIAO- Clear Mechanism Brought Great Advantages Faster Acting, Higher Safety Differential Signaling Transduction of TPO VS Romiplostim and Eltrombopag • TPIAO combines extracellular C-MPL receptor, simultaneously activates JAK-STAT, MAPK, Structure kept high consistent with PI3K-AKT channels endogen
Slide 13: TPIAO - Sustainably Expand Cancer Induced TCP Market
TPIAO- Sustainably Expand Cancer Induced TCP Market Chemotherapy TCP Patients Radiotherapy TCP Patients Surgery TCP Patients 1+ Mn patients, main indication 300+ K patients, if PLT < 75*109 , 200+ K patients, PLT of large covered by cancer TCP, continuous the drop-off rate of treatment wound surgery
Slide 14: EPIAO & SEPO - Recombinant Human Erythropoietin
EPIAO & SEPO- Recombinant Human Erythropoietin Revenue of rhEPO, 2022 TOP 1 Market Share 1 Two brands dominate 44.5% market share, Top 1 in EPO market RMB Mn YOY：0.9% 44.5% EPIAO&SEPO rhEPO A 1,120 1,129 rhEPO B 974 897 749 rhEPO C rhEPO D Others 2018 2019 2020 2021 2022 14
Slide 15: rhEPO - Sustained Growth Driven by Demand
rhEPO- Sustained Growth Driven by Demand Guideline recommendations increase, Treatment barriers removed, Clinical demand for EPO rise • Renal anemia treatment QC standards for hemoglobin 36% Dialysis anemia penetration rate1 enhanced2, the demand for EPO further increased • EPO was added in various
Slide 16: Yisaipu - Explore to Reform
Yisaipu- Explore to Reform Revenue of Yisaipu, 2022 The first biopharmaceutical for the treatment of chronic disease 18 years of clinical application experience in Chinese patients RMB Mn Demand rebounds to growth The demand for treatment of chronic diseases has returned to normal Develop new formul
Slide 17: Cipterbin - Enter High-speed Growing Period
Cipterbin- Enter High-speed Growing Period Release Release Revenue of Cipterbin, 2022 Guideline Subject Time Recommendation Treatment Advanced breast cancer first- Guidelines for CSCO 2022 line treatment Breast Cancer (2022) recommendations RMB Mn 2022 NRDL NHC 2023 Remove the limitation of combinat
Slide 18: Hair Healthiness
1 8 Hair Healthiness
Slide 19: Mandi - Effective & Reliable Hair Product
Mandi- Effective & Reliable Hair Product Revenue of Mandi, 2022 Top 1 Market Share 1 71.7% Market Share, secured top 1 minoxidil 1 RMB Mn YOY：48.1% 71.7% Mandi 891 Minoxidil A Minoxidil B 602 Other 368 minoxidil 250 94 127 2017 2018 2019 2020 2021 2022 1. Data source：CPA 19
Slide 20: Mandi - 3 Channels Propel Sales Increase
Mandi- 3 Channels Propel Sales Increase Retail Hospital E-commerce Pharmacy 14% of revenue, 2%YOY 25% of revenue, 65%YOY 60% of revenue, 58%YOY • Annually reached 20 million plus people, • Academic recognition continues to 3 million plus customers improve, recommendations of the • 100K Pharmacy, cov
Slide 21: Mandi - Build Abundant Product Matrix
Mandi- Build Abundant Product Matrix Mandi Mandi white bottle 01 60/90mL Male monthly 02 30mL Female monthly course, course convenient and certain amount controllable Mandi foam Mandi Pro (portable version) 03 Upcoming soon, fill hair-loss 04 10mL, Equipped with diverse market for sensitive hair ski
Slide 22: CDMO
2 2 CDMO
Slide 23: CDMO - Domestic Pioneer of CDMO
CDMO- Domestic Pioneer of CDMO Revenue of CDMO, 2022 Formulations Biopharmaceuticals GCT Biopharmaceutical RMB Mn YOY：49.6% 53% yoy 43% yoy 1 166 Revenue from Revenue from Commercialized overseas domestic product subsidiary subsidiary 106 111 100 100Mn+ 2019 2020 2021 2022 Backlogs 76 KL capacities
Slide 24: CDMO - Advancing Construction
CDMO- Advancing Construction 12Mn vias formulation gradually Stage I 2000L disposable operated after Q4 2022, fourfold capacity and 40Mn vias expansion after full operation formulation completed; Stage II affinity resin and culture medium started construction Powder- injection/ Freeze- dried powder-
Slide 25: R&D Review
a) 0 o o So
Slide 26: R&D Pipeline
R&D Pipeline Therapeutic Area Candidates TPO-105 Pediatric ITP Pre-clinical IND Phase I Phase II Phase III NDA NDA 4 TPO-106 CLDT Pre-clinical SSS06 Long-acting rhEPO RD01 Long-acting rhEPO Nephrology SSS17 HIF inhibitor SSS20 Eltrombobag SSS12 Cinacalcet hydrochloride BE ANDA 4 SSS13 Sevelamer carb
Slide 27: R&D Outlook - Upcoming Commercialization Boom
R&D Outlook- Upcoming Commercialization Boom Saiboning AmBisome Remitch TPIAO Tofacitinib Sevelamer NDA/ANDA Reviewing YSP Mandi Nadroparin Calcium Amphotericin B Narfuraphine liposome for Pre-filled Foam API and & Injection hydrochloride orally Pediatric ITP Tablet injection disintegrating tablets
Slide 28: Key Candidates: SSS06 (Long-acting rhEPO)
Key Candidates: SSS06 (Long-acting rhEPO) Phase II clinical trial data indicate safety and efficacy rhEPO VS SSS06 clinical efficacy data: rhEPO rESA QW rESA QOW • 2nd-generation EPO， extend half -life for 2 (Screening Dose) （0.5ug/kg） （1.0ug/kg） weeks dosing intervals, match treatment cycles of che
Slide 29: Key Candidates: Anti-IL17A mAb (608)
Key Candidates: Anti-IL17A mAb (608) Phase II data shows specific efficacy in PsO patients Week 12 primary endpoint data of 608, Secukinumab, Ixekizumab in PsO patients Week 12 Data shows the efficacy of 608 at different doses is much better than placebo group & marketed products, indicating Best-In
Slide 30: Key Candidates: Anti-IL1β mAb (613)
Key Candidates: Anti-IL1β mAb (613) Effectively Relieved Pains in Acute Gout Arthritis VAS pain scores of target joint declined • Data from phase Ib trial in AG arthritis shows the VAS scores of 613 in similar to Canakinumab different doses are improved significantly relative to the baseline 100 mg
Slide 31: Key Candidates: Anti-IL4R mAb (611)
Key Candidates: Anti-IL4R mAb (611) Phase Ib Data shows rapid response rate of 611 in severe AD patients • The data from week 16 shows 611 takes effect 611 & Dupilumab: EASI-50, EASI-90, EASI % of Reduction Relative to the Baseline in moderate-to-severe AD patients after 2 120 weeks doses • Rapid re
Slide 32: Key Candidates: Anti-IL5 mAb (610)
Key Candidates: Anti-IL5 mAb (610) Significantly Improve the pulmonary function of severe asthma patients The analysis of phase Ib blinding clinical trial shows FEV1 is enhanced • Progress ranks NO.1 in China 0.45 0.424 0.4 Company Code Indication 0.35 0.3 0.271 Phase II in eosinophil asthma is in S
Slide 33: Three Bispecific Antibody Platforms
Three Bispecific Antibody Platforms Linker CH2 CH3 o Form Quadrivalent BsAb with symmetric structure o Support personalized design and multivalent BsAb & o VHH/ IgSF unique BsAb platform based on trispecific Ab production of two same heavy chains and four same light Nanobody chains o Stable scFv, Li
Slide 34: Key Candidates - Remitch
Key Candidates- Remitch Remitch (Narfuraphine hydrochloride orally disintegrating tablets) First-line Drugs for Liver& Kidney Disease Pruritus in Exclusive product，Focus on Millions of Nephrology Japan Guidelines Patients’ Clinical Demands 日本肝肾疾病瘙痒指南一线用药 Uremic pruritus (UP) -2009 Chronic Liver Dise
Slide 35: Key Candidates - Remitch
Key Candidates- Remitch First and Only Symptomatic Drug Liver Disease related Pruritus 1 Become the first and only domestic drug in dialysis pruritus after approved, resolve problems such as respiratory depression, constipation and addiction brought by traditional opioids 57% Targeted Patients Dialy
Slide 36: International Cooperation - License in
International Cooperation- License in Clascoterone (WS204) Innovative product to exploit the huge potential of Chinese market 1st in Class AR target drug to treat acne • In July 2022, 3SBio Partnered with Cosmo and licensed in the exclusive right of Winlevi® (clascoterone cream 1%) to treat acne in
Slide 37: International Cooperation - License out
International Cooperation- License out SSS11 Pegsiticase 609A Cipterbin PEG-modified Recombinant Humanized Inetetamab (PEG-modified anti-PD-1 mAb Recombinant (PEG-modified Recombinant (PEG-modified Recombinant Uricase Recombinant • • Global development • Produced by C. utillis, Global development an
Slide 38: Financial Review
04 Financial Review
Slide 39: Financial Analysis
Financial Analysis Revenue Gross Profit RMB Bn RMB Bn YoY：7.5% YoY：7.5% 6.4 6.9 5.7 5.3 5.6 5.3 4.6 4.4 4.5 3.7 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 NI Attributable to Parent NORM NI Attributable to Parent RMB Bn RMB Bn YoY ：16.0% YoY ：25.2% 1.9 2.2 1.7 1.7 1.3 1.4 1.0 0.8 1.2 1.2 2018
Slide 40: Expense Management
Expense Management Selling and Distribution Expenses RMB Bn Administrative Expenses RMB Mn 2.6 Equity Incentive Administrative 2.0 2.3 1.7 2.0 0 2018 2019 2020 2021 2022 S&D Ratio 36.9% 36.7% 36.1% 36.4% 亿元 37.6% R&D Costs 亿元 330 352 340 374 RMB Mn 299 754 693 2018 2019 2020 2021 2022 527 590 363 20
Slide 41: Total Assets & Debt
Total Assets & Debt Total Assets RMB Bn Debt Asset Ratio 40% 22.0 35.6% 17.7 19.2 13.8 14.8 30.1% 30.0% 30% 2018 2019 2020 2021 2022 25.9% 23.7% 20.1% 19.0% 20% Net Assets 14.5% 12.0% 11.9% RMB Bn 10% Include CB Exclude CB 14.7 15.4 0% 13.1 8.9 10.4 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022
Slide 42: Sublime CF Condition, Sufficient FCF
Sublime CF Condition, Sufficient FCF OCF Cash Equivalents (Financing Proceeds Included) RMB Bn RMB Bn YoY ：38.2% 2.2 7.4 1.9 1.6 5.0 1.3 4.5 1.2 2.6 1.9 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 42
Slide 43: Extremely Attractive Earnings
Extremely Attractive Earnings EPS ROE RMB YoY : 20.0% 0.78 14.3% 12.4% 0.65 11.1% 0.50 9.5% 0.38 0.33 5.9% 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 43
Slide 44: Sustain Robust Growth, Repay Shareholders
Sustain Robust Growth, Repay Shareholders Net Income attributable to parent 5 years of CAGR 10.7% TPIAO Cipterbin Mandi R&D Robust Exclusive First-line Drug New Launch Performance Top 1 Brand Product Deliver sustainable Successful NRDL Improve clinical Advanced penetration rate, 10 new products1 are
Slide 45: Q&A
05 Q&A
Slide 46: THANKS
THANKS 3SBio Inc. (1530.HK) Investor Relations ir@3sbio.com 珍 爱 生 命 · 关 注 生 存 · 创 造 生 活 CHERISH LIFE CARE FOR LIFE CREATE LIFE